The importance of IFN-stimulated genes in the clinical outcome of GBM patients is demonstrated by the discovery of a three-gene risk model combining STAT3, STAT2, and SOCS3 as an independent predictor in the context of GBM [125]. The gene discussed is STAT3; the disease is glioblastoma.